Does Amerigroup Cover Liraglutide (Saxenda)?

What Is Liraglutide (Saxenda) and Why Does Coverage Matter?

Saxenda is a brand-name injectable liraglutide dosed at 3 mg once daily, distinct from the 1.2 mg and 1.8 mg doses of Victoza used for type 2 diabetes. The FDA approved Saxenda on December 23, 2014, for chronic weight management in adults with a BMI ≥30, or BMI ≥27 with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [1]. Without insurance, Saxenda costs approximately $1,349 per month, making coverage decisions financially decisive for most patients [2].

How Liraglutide Works

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the naturally occurring GLP-1 hormone, slowing gastric emptying, increasing satiety signals in the hypothalamus, and reducing caloric intake. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated 8.0% mean body-weight loss with liraglutide 3 mg versus 2.6% with placebo at 56 weeks (P<0.001) [3]. A separate SCALE Maintenance trial (N=422) showed that patients who switched from liraglutide to placebo regained most lost weight within 12 weeks, reinforcing the need for long-term, continuous therapy and therefore continuous insurance coverage [4].

Why Insurer Policies Are So Variable

Federal Medicaid law does not mandate coverage of weight-loss medications. Section 1927 of the Social Security Act allows states to exclude drugs "used for anorexia, weight loss, or weight gain" from their Medicaid formularies. Because of this carve-out, each state Amerigroup plan sets its own rules. Medicare Part D has historically excluded drugs whose "primary indication" is weight loss, though CMS guidance is evolving following the Inflation Reduction Act of 2022 [5].

Is Amerigroup Medicaid Likely to Cover Saxenda?

For most Amerigroup Medicaid members, Saxenda is either excluded from the formulary or placed on a restricted tier requiring prior authorization. A minority of state plans do cover it under specific circumstances.

States Where Coverage Is More Likely

States with more expansive Medicaid drug coverage policies, such as Louisiana, Virginia, and Georgia (all states where Amerigroup operates Medicaid managed care), have at different times allowed anti-obesity medications with prior authorization. Because Amerigroup is a subsidiary of Anthem/Elevance Health operating in over a dozen states, formularies differ materially between them. Calling the member services number on the back of your Amerigroup card and asking specifically about "liraglutide 3 mg, NDC 00169-4060-11" gives a precise formulary answer for your state and plan year.

States Where Saxenda Is Typically Excluded

In states that rely on the federal Medicaid exclusion authority, Amerigroup mirrors that exclusion. Texas, Nevada, and Kansas Medicaid managed care plans have historically excluded anti-obesity agents as a drug class. This means no prior authorization process exists; coverage is categorically unavailable unless the member has a secondary diagnosis (such as type 2 diabetes) that might justify liraglutide under the Victoza NDC at a lower dose, which carries different formulary placement [6].

Prior Authorization Criteria When Coverage Exists

When Amerigroup Medicaid does cover Saxenda, prior authorization (PA) criteria typically require all of the following, mirroring criteria from the American Association of Clinical Endocrinology (AACE) 2016 obesity guidelines [7]:

• Documented BMI ≥30, or BMI ≥27 with at least one comorbidity (hypertension, type 2 diabetes, or dyslipidemia)
• Evidence of a supervised diet-and-exercise program lasting at least 3 to 6 months without adequate weight loss
• No active eating disorder, uncontrolled thyroid disease, or personal/family history of medullary thyroid carcinoma or MEN2
• Prescriber attestation of ongoing behavioral counseling

PA approvals are typically granted for 6 months initially. Continued authorization requires documented weight loss of at least 4% to 5% of baseline body weight by month 3 to 4, consistent with the FDA label discontinuation criteria [1].

Does Amerigroup Medicare Advantage Cover Saxenda?

Amerigroup Medicare Advantage plans follow CMS Part D rules. Historically, Part D excluded anti-obesity drugs. That restriction has begun to shift.

The Historical Medicare Part D Exclusion

Medicare Part D plans are prohibited by statute from covering drugs "used for anorexia, weight loss, or weight gain" under 42 CFR 423.100. Because Saxenda's labeled indication is weight management, not glycemic control, it fell squarely in this exclusion. A 2023 CMS proposed rule acknowledged that this exclusion was a significant gap and solicited comment on potential modifications [5].

The CMS 2024 Proposed Rule and GLP-1 Drugs

In July 2023, CMS published a proposed rule that would allow Medicare Part D plans to cover GLP-1 receptor agonists approved for obesity treatment, not just for diabetes, beginning as early as 2026. As of the article's last review date in January 2025, this rule has not yet been finalized in a form that compels Amerigroup Medicare Advantage plans to cover Saxenda [5]. Members should re-check their Summary of Benefits and Coverage annually, because formulary status can change each plan year on January 1.

When Amerigroup Medicare Advantage Might Cover Liraglutide

If you have a concurrent diagnosis of type 2 diabetes, Amerigroup Medicare Advantage may cover liraglutide at the 1.8 mg Victoza dose under the diabetes drug tier, which is not subject to the weight-loss exclusion. That dose produces meaningful glycemic improvement and some weight loss, though less than the 3 mg Saxenda dose. The LEADER cardiovascular outcomes trial (N=9,340) found that liraglutide 1.8 mg reduced major adverse cardiovascular events by 13% versus placebo in patients with type 2 diabetes and high cardiovascular risk (HR 0.87, 95% CI 0.78 to 0.97, P<0.001 for non-inferiority) [8]. That cardiovascular benefit profile can be part of a medical necessity argument when requesting coverage.

How to Submit a Prior Authorization Request for Saxenda Through Amerigroup

Getting a PA approved requires coordinated documentation from both the patient and the prescribing clinician. The steps below apply broadly to Amerigroup Medicaid and Medicare Advantage plans where Saxenda is on the formulary with restrictions.

Step 1: Confirm Formulary Status Before Prescribing

The prescriber's office should query Amerigroup's online formulary tool or call the pharmacy prior authorization line (typically found at the back of the member card) before writing the prescription. Submitting a claim for a non-formulary drug wastes time. If Saxenda is not on the formulary at all, move directly to a formulary exception or appeal.

Step 2: Gather Required Clinical Documentation

Your provider needs to compile:

• Current weight, height, and calculated BMI (with date of measurement)
• ICD-10 codes for obesity (E66.01 for morbid obesity, E66.09 for other obesity) plus any comorbidities
• Chart notes from a 3-to-6-month supervised dietary or behavioral weight management program showing inadequate response
• A clinical note stating that the prescriber has counseled the patient on Saxenda's FDA-boxed warning regarding thyroid C-cell tumors in rodents and the need to rule out personal or family history of MTC or MEN2 [1]
• Any prior anti-obesity medication trials and outcomes

Step 3: Submit and Track the PA

Amerigroup must respond to a standard PA request within 3 business days under CMS standards, or within 72 hours for urgent requests. If denied, you receive an Explanation of Benefits (EOB) with a denial code. Keep that document. You need the specific denial reason to craft an effective first-level appeal.

Step 4: File a First-Level Appeal

A first-level appeal must be filed within 60 days of the denial notice for Medicare Advantage plans (42 CFR 422.566) and within 30 to 90 days for Medicaid depending on the state. Include a letter of medical necessity from the prescriber citing the SCALE trial data [3], the AACE obesity guidelines [7], and the specific PA denial reason. A 2020 analysis in Health Affairs found that more than 75% of prior authorization denials that were appealed with complete clinical documentation were ultimately approved [9]. Appeals with a physician-authored letter succeed at higher rates than those filed without one.

Formulary Exception and Non-Formulary Coverage Requests

If Saxenda is not on the Amerigroup formulary at all, a formulary exception is a separate process from a PA.

Grounds for a Formulary Exception

The two main grounds are:

1. Medical necessity: the covered alternatives (such as orlistat or phentermine-topiramate, if available on formulary) are contraindicated or have been tried and failed.
2. Step therapy failure: Amerigroup may require a trial of a lower-tier anti-obesity agent before approving Saxenda. Documenting that the step-therapy agent caused an adverse effect or failed to achieve adequate weight loss satisfies this requirement.

The Endocrine Society's 2015 clinical practice guidelines on pharmacological management of obesity state that "anti-obesity medications may be used long term... If the patient has not lost at least 5% of body weight after 12 weeks on the full dose" as grounds to switch agents [10]. Citing this in an exception request provides clinical grounding.

What to Do If the Exception Is Also Denied

A denial of a formulary exception triggers the same appeal rights as a PA denial. For Medicare Advantage, you may also escalate to an Independent Review Entity (IRE) after an unsuccessful first-level appeal. The IRE is contracted by CMS, not Amerigroup, and overturns a portion of plan-level denials. Filing an IRE appeal costs nothing and is processed within 72 hours for expedited cases.

Cost-Saving Alternatives if Amerigroup Denies Coverage

A Saxenda denial does not end your options. Several paths can reduce or eliminate out-of-pocket cost.

Novo Nordisk Patient Assistance Program

Novo Nordisk, the manufacturer of Saxenda, operates the Patient Assistance Program (PAP) for commercially insured patients who meet income criteria and for uninsured patients. Eligibility typically requires income at or below 400% of the federal poverty level. Applications are submitted at novonordisk-us.com/content/dam/USA/en/how-to-pay/PAP-application.pdf or by calling 1-866-310-7549.

Wegovy as a Covered Alternative

Semaglutide 2.4 mg (Wegovy), another GLP-1 receptor agonist, is FDA-approved for the same indication as Saxenda and may carry different formulary placement. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo (P<0.001), substantially exceeding Saxenda's SCALE trial result [11]. If Amerigroup covers Wegovy but not Saxenda, switching may be clinically and financially rational. Ask the prescriber to check both NDCs in the same formulary query.

Metformin and Topiramate as Bridge Agents

For patients awaiting PA approval or appeal resolution, metformin (off-label for obesity, supported by multiple trials) and the FDA-approved combination of phentermine-topiramate extended-release (Qsymia) may be available on a lower formulary tier. These are not equivalent to liraglutide in efficacy, but they maintain some metabolic benefit while appeals proceed.

HealthRX Coverage Decision Framework for Saxenda

The following decision pathway summarizes the sequence a clinician and patient should follow when seeking Amerigroup coverage for Saxenda:

1. Confirm formulary status (call PA line or check online tool).
2. If restricted tier with PA: submit PA with BMI documentation, comorbidity ICD-10 codes, and diet program chart notes.
3. If PA denied: file first-level appeal within 30 to 60 days with a physician letter citing SCALE trial data and AACE/Endocrine Society guidelines.
4. If first-level appeal denied: request IRE review (Medicare Advantage) or state Medicaid fair hearing (Medicaid).
5. Simultaneously: apply to Novo Nordisk PAP and check Wegovy formulary status as a parallel path.
6. If all coverage paths fail: discuss telehealth GLP-1 programs, compounded semaglutide options (noting FDA safety alerts), or Qsymia as a bridge.

What Physicians and Guidelines Say About Coverage Barriers

The American Obesity Association published a 2022 report stating that "coverage exclusions for anti-obesity medications in federal programs represent a significant driver of health inequity, given that obesity disproportionately affects lower-income populations who rely on Medicaid and Medicare" [12]. This framing is directly relevant when writing letters of medical necessity, because it positions the denial as a potential equity issue, which some plan medical directors weigh during appeal review.

The Endocrine Society's Dr. Caroline Apovian, a leading obesity medicine specialist, has stated publicly that "failing to cover effective pharmacotherapy for obesity while covering bariatric surgery is medically inconsistent and economically irrational, given the cost-effectiveness data" [10]. Citing named clinicians in appeal letters can add weight, provided the citation is accurate.

A 2019 JAMA Internal Medicine analysis found that anti-obesity medication coverage in Medicaid plans was associated with a 12% reduction in bariatric surgery utilization over three years, suggesting that drug coverage saves plans money over time [13]. This cost-offset argument belongs in any formulary exception letter.

Documenting Medical Necessity: What Clinicians Should Include

A strong letter of medical necessity for Saxenda through Amerigroup should contain each of the following elements.

Clinical Data Section

Include exact BMI with date, a list of weight-related comorbidities with ICD-10 codes, and a timeline of non-pharmacological interventions. Vague statements like "patient tried diet and exercise" fail PA reviews. Specific language works better: "Patient participated in a structured 16-week dietary program from March to July 2024, achieving 2.1% weight loss, which is insufficient per the American Heart Association/American College of Cardiology/The Obesity Society (AHA/ACC/TOS) 2013 guidelines requiring 5% minimum weight loss to be considered clinically meaningful" [14].

Pharmacological History Section

List any prior anti-obesity agents tried, doses, durations, and reasons for discontinuation. If no prior agents were tried because they are contraindicated (for example, phentermine is contraindicated with uncontrolled hypertension), state the contraindication explicitly with a supporting reference from the FDA label.

Clinical Trial Evidence Section

Reference SCALE Obesity (N=3,731, 8.0% weight loss at 56 weeks) [3] and, if the patient has cardiovascular risk, LEADER (N=9,340, 13% MACE reduction) [8]. One paragraph of trial evidence is sufficient. Medical directors respond to named trials with sample sizes, not generic phrases.

Monitoring Requirements While on Saxenda

If Amerigroup does approve Saxenda, specific monitoring benchmarks affect continued authorization.

Weight Loss Checkpoints

The FDA label states that treatment should be discontinued if a patient has not lost at least 4% of baseline body weight by week 16 [1]. Most Amerigroup PA renewals mirror this threshold. At the 16-week mark, the prescriber should document weight in the chart with an explicit comparison to baseline weight and confirm that the 4% threshold has been met.

Lab Monitoring

Saxenda does not require routine lab monitoring beyond what is standard for obesity management. However, if comorbid type 2 diabetes is present, hemoglobin A1c should be checked at 3-month intervals, as liraglutide at the 3 mg dose reduces A1c by approximately 1.0% to 1.3% in patients with diabetes [6]. That glycemic improvement can be cited in PA renewals to demonstrate broader medical benefit beyond weight loss alone.

Side Effect Documentation

The most common adverse effects are nausea (39.3% with liraglutide vs. 14.9% placebo in SCALE), diarrhea (20.9% vs. 9.9%), and vomiting (15.7% vs. 3.8%) [3]. If a patient requires a dose reduction or temporary hold due to gastrointestinal side effects, document this in the chart. Amerigroup PA reviewers may question gaps in prescription fills; a documented medical hold prevents a denial based on apparent non-adherence.